A streak of exciting new drug trials has helped Intermune triple in 2014. Can this biotech player give your portfolio a shot in the arm? Jim Cramer speaks with its …
source CNBC
InterMune Inc. CEO Dan Welch | Mad Money | CNBC
previous post